Drug Search Results
More Filters [+]

Lontucirev

Alternative Names: lontucirev, onyx-015, onyx015, onyx 015
Latest Update: 2023-12-21
Latest Update Note: PubMed Publication

Product Description

An E1B-55kDa-deleted adenovirus that is able to selectively replicate in and lyse TP53-deficient human tumor cells.

Mechanisms of Action: p53 Activator

Novel Mechanism: Yes

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lontucirev

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oropharyngeal Cancer|Head and Neck Cancer|Mouth Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DFCI-98320

P1

Withdrawn

Oropharyngeal Cancer|Head and Neck Cancer|Mouth Cancer

None

Recent News Events